Management of neuropathic bladder secondary to spina bifida: Twenty years' experience with a conservative approach

Hesham Elagami, Tariq O Abbas, Kathryn Evans, Feilim Murphy, Hesham Elagami, Tariq O Abbas, Kathryn Evans, Feilim Murphy

Abstract

Introduction: Treatment of neuropathic bladder secondary to spina bifida is an ongoing challenge. Although different management strategies and protocols are available in the literature, reliance on expert opinion remains fundamental. A conservative approach can be utilized, but patients must be closely monitored throughout the management process. The objective of this study was to review the management and outcomes of neuropathic bladder in spina bifida by appraising long-term bladder and renal function in patients treated at a medical center utilizing a conservative management style.

Methods: This is a single-center retrospective review of urology care for all spina bifida patients 5-19 years of age with a neuropathic bladder who attended follow-ups between April 2000 and April 2020. Only patients with more than 5 years of follow-up were included. Renal functions, continence and results of invasive video urodynamics (IUD) and any surgical interventions were recorded.

Results: Seventy-one patients (mean age = 10.5 years) were identified after exclusions. Bladder compliance between first and last IUDs increased significantly (p = 0.0056). Anticholinergic treatment was started at the first outpatient appointment. Intravesical botulinum toxin injection was the second line treatment in ten patients. 94% of patients had an end fill pressure below 40 cm H2O in their last IUD. 82% were socially continent (dry or occasional damp patches) with or without catheterisations at the age of 11.5 years. One patient in the cohort had bladder augmentation.

Conclusion: The optimal management of neuropathic bladder secondary to spina bifida remains controversial. Bladder and renal functional outcomes can be improved with close monitoring and less invasive management.

Keywords: conservative; intermittent catheterisation; management; neuropathic bladder; spina bifida; urodynamics.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Elagami, Abbas, Evans and Murphy.

Figures

Figure 1
Figure 1
Bladder capacity – observed/expected (O/E) ratio (mL/mL) at first and last recorded IUDs. Fifty-four patients who had more than one test available were included. Statistical significance was assessed using paired t-test, and a p-value < 0.05 was considered significant. IUD, invasive video urodynamics.
Figure 2
Figure 2
Bladder compliance (mL/cm H2O) at first and last recorded IUDs. Fifty-four patients who had more than one test available were included. Statistical significance was assessed using paired t-test, and a p-value < 0.05 was considered significant. IUD, invasive video urodynamics.

References

    1. Nijman RJM, Tekgül S. Pathophysiology of neurogenic bladder dysfunction. In: Esposito C, Guys JM, Gough D, Savanelli A, editors. Pediatric Neurogenic Bladder Dysfunction. Berlin; Heidelberg: Springer; (2006). p. 33–8.
    1. Bauer SB. The management of the myelodysplastic child: a paradigm shift. BJU Int. (2003) 92:23–8. 10.1046/j.1464-410X.92.s1.2.x
    1. Rensing AJ, Szymanski KM, Misseri R, Roth JD, King S, Chan K, et al. . Radiographic abnormalities, bladder interventions, and bladder surgery in the first decade of life in children with spina bifida. Pediatr Nephrol. (2019) 34:1277–82. 10.1007/s00467-019-04222-w
    1. Lee B, Featherstone N, Nagappan P, McCarthy L, O'Toole S. British association of paediatric urologists consensus statement on the management of the neuropathic bladder. J Pediatr Urol. (2016) 12:76–87. 10.1016/j.jpurol.2016.01.002
    1. Generao SE, Dall'era JP, Stone AR, Kurzrock EA. Spinal cord injury in children: long-term urodynamic and urological outcomes. J Urol. (2004) 172:1092–4. 10.1097/
    1. Nevéus T, von Gontard A, Hoebeke P, Hjälmås K, Bauer S, Bower W, et al. . The standardization of terminology of lower urinary tract function in children and adolescents: report from the standardisation committee of the international children's continence society. J Urol. (2006) 176:314–24. 10.1016/S0022-5347(06)00305-3
    1. Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. . The standardization of terminology of lower urinary tract function in children and adolescents:u report from the standardization committee of the international children's continence society. Neurourol Urodyn. (2016) 35:471–81. 10.1002/nau.22751
    1. Vaidya SR, Aeddula NR. Chronic Renal Failure. StatPearls. (2022).
    1. Farhat W, Bägli DJ, Capolicchio G, O'Reilly S, Merguerian PA, Khoury A, et al. . The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. J Urol. (2000) 164:1011–5. 10.1097/00005392-200009020-00023
    1. Peeraully R, Lam C, Mediratta N, Patel R, Williams A, Shenoy M, et al. . Intradetrusor injection of botulinum toxin A in children: a 10-year single centre experience. Int Urol Nephrol. (2019) 51:1321–7. 10.1007/s11255-019-02185-3
    1. Tanaka ST, Yerkes EB, Routh JC, Tu DD, Austin JC, Wiener JS, et al. . Urodynamic characteristics of neurogenic bladder in newborns with myelomeningocele and refinement of the definition of bladder hostility: findings from the UMPIRE multi-center study. J Pediatr Urol. (2021) 17:726–32. 10.1016/j.jpurol.2021.04.019
    1. Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol. (2006) 175:1102–5. 10.1016/S0022-5347(05)00400-3
    1. Malakounides G, Lee F, Murphy F, Boddy S-A. Single centre experience: long term outcomes in spina bifida patients. J Pediatr Urol. (2013) 9:585–9. 10.1016/j.jpurol.2013.02.015
    1. Imamura M, Hayashi C, Kim WJ, Yamazaki Y. Renal scarring on DMSA scan is associated with hypertension and decreased estimated glomerular filtration rate in spina bifida patients in the age of transition to adulthood. J Pediatr Urol. (2018) 14:317.e1–e5. 10.1016/j.jpurol.2018.07.023
    1. Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. (1972) 107:458–61. 10.1016/S0022-5347(17)61055-3
    1. Sager C, Barroso U, Bastos JM, Retamal G, Ormaechea E. Management of neurogenic bladder dysfunction in children update and recommendations on medical treatment. Int Braz J Urol. (2022) 48:31–51. 10.1590/s1677-5538.ibju.2020.0989
    1. Kaye IY, Payan M, Vemulakonda VM. Association between clean intermittent catheterization and urinary tract infection in infants and toddlers with spina bifida. J Pediatr Urol. (2016) 12:284.e1–e6. 10.1016/j.jpurol.2016.02.010
    1. Woo J, Palazzi K, Dwek J, Kaplan G, Chiang G. Early clean intermittent catheterization may not prevent dimercaptosuccinic acid renal scan abnormalities in children with spinal dysraphism. J Pediatr Urol. (2014) 10:274–7. 10.1016/j.jpurol.2013.09.001
    1. Timberlake MD, Kern AJ, Adams R, Walker C, Schlomer BJ, Jacobs MA. Expectant use of CIC in newborns with spinal dysraphism: Report of clinical outcomes. J Pediatr Rehabil Med. (2017) 10:319–25. 10.3233/PRM-170464
    1. Higuchi TT, Granberg CF, Fox JA, Husmann DA. Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy. J Urol. (2010) 184:2492–6. 10.1016/j.juro.2010.08.038
    1. Vajda P, Kispal Z, Lenart I, Farkas A, Vastyan AM, Pinter AB. Quality of life: urinary bladder augmentation or substitution in children. Pediatr Surg Int. (2009) 25:195–201. 10.1007/s00383-008-2317-3
    1. Soergel TM, Cain MP, Misseri R, Gardner TA, Koch MO, Rink RC. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol. (2004) 172:1649–51. 10.1097/01.ju.0000140194.87974.56
    1. Husmann DA. Malignancy after gastrointestinal augmentation in childhood. Ther Adv Urol. (2009) 1:5–11. 10.1177/1756287209104163
    1. Lemelle JL, Simo AK, Schmitt M. Comparative study of the Yang-Monti channel and appendix for continent diversion in the Mitrofanoff and Malone principles. J Urol. (2004) 172:1907–10. 10.1097/01.ju.0000140448.36332.fc
    1. Horst M, Weber DM, Bodmer C, Gobet R. Repeated Botulinum-A toxin injection in the treatment of neuropathic bladder dysfunction and poor bladder compliance in children with myelomeningocele. Neurourol Urodyn. (2011) 30:1546–9. 10.1002/nau.21124
    1. Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urol. (2002) 59:325–7. 10.1016/S0090-4295(01)01641-7
    1. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. . Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. (2005) 174:196–200. 10.1097/01.ju.0000162035.73977.1c
    1. Blackburn SC, Jones C, Bedoya S, Steinbrecher HA, Malone PS, Griffin SJ. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children. J Pediatr Urol. (2013) 9:750–3. 10.1016/j.jpurol.2012.08.011
    1. Naqvi S, Clothier J, Wright A, Garriboli M. Urodynamic outcomes in children after single and multiple injections for overactive and low compliance neurogenic bladder treated with abobotulinum toxin A. J Urol. (2020) 203:413–9. 10.1097/JU.0000000000000540
    1. Hascoet J, Peyronnet B, Forin V, Baron M, Capon G, Prudhomme T, et al. . Intradetrusor injections of botulinum toxin type A in children with spina bifida: a multicenter study. Urol. (2018) 116:161–7. 10.1016/j.urology.2018.02.033

Source: PubMed

Подписаться